Cost effectiveness of difelikefalin for the treatment of patients with chronic kidney disease-associated pruritus undergoing hemodialysis in Italy
Difelikefalin was found to be a cost-effective treatment for the Italian NHS. These results support its reimbursement and its inclusion in routine clinical practice.
Authors
- Lucio Manenti (ORCID: https://orcid.org/0000-0002-4144-2142)
- Eugenio Di Brino (ORCID: https://orcid.org/0000-0001-7964-3348)
- Andrea Marcellusi (ORCID: https://orcid.org/0000-0002-3974-3798)
- Patrizia Berto (ORCID: https://orcid.org/0000-0002-9041-6258)
- Andrea Aiello
- Marco Soro
- Asia Barugolo
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Milan (IT)
- Vifor Pharma (Switzerland) (CH)
- Società Italiana di Nefrologia (IT)
- Vifor Pharma (United States) (US)
Publication Details
- Journal
- Journal of Nephrology
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1007/s40620-024-02144-x
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00